Hormonal
Semaglutide (2.4 mg once weekly) and Tirzepatide (up to 15 mg once weekly) produce significant weight loss (up to 14.9-20.9%) and improved glycemic control (HbA1c reduction >2%) in adults with obesity or type 2 diabetes, outperforming placebo and existing pharmacotherapies.
Semaglutide and Tirzepatide are highly effective, once-weekly injectable treatments for obesity and type 2 diabetes. They work by mimicking hormones that regulate appetite and blood sugar, leading to significant weight loss (up to 20%) and better glucose control than most other drugs. Because weight regain is common after stopping, these medications are intended for long-term management of these chronic conditions, not short-term fixes.
Clinical trials, such as the STEP and SURPASS programs, demonstrate that semaglutide and tirzepatide achieve weight loss of up to 20.9% of initial body weight, comparable to bariatric surgery, and HbA1c reductions exceeding 2%, surpassing the 0.5% to 2% reductions typically observed with other T2DM therapies.
Why this rating
Based on multiple large-scale, randomized, placebo-controlled clinical trials (STEP 1-4, SURPASS 1-5, SURMOUNT-1).
Source
Semaglutide and Tirzepatide: Revolutionary Therapies for Obesity and Type 2 Diabetes Mellitus Management
James P. Torres-Pirela · Ponce Health Sciences University Scientific Journal · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →